Hoth restates 2023, 2024 financials for prepaid R&D errors; initiates HT-KIT toxicity study

Hoth Therapeutics, Inc.

Restatement: prepaid expenses understated by $722,765 at Dec 31, 2023; R&D expenses understated by $260,732 for FY2023.
Quarterly restatements for 2023-2024: prepaid assets understated by $442k-$983k; R&D expenses understated by $52k-$280k.
Enters Project Order with OnTargetx for 4-week IV toxicity study of HT-KIT (mast cell cancer) at cost of $354,219.
Restatement impacts operating cash flows but total cash unchanged; 2024 10-K to include restated periods.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.